<?xml version='1.0' encoding='utf-8'?>
<document id="29790819"><sentence text="Effects of astragaloside IV on the pharmacokinetics of puerarin in rats."><entity charOffset="11-27" id="DDI-PubMed.29790819.s1.e0" text="astragaloside IV" /><entity charOffset="55-63" id="DDI-PubMed.29790819.s1.e1" text="puerarin" /><pair ddi="false" e1="DDI-PubMed.29790819.s1.e0" e2="DDI-PubMed.29790819.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29790819.s1.e0" e2="DDI-PubMed.29790819.s1.e1" /></sentence><sentence text="Radix astragali and puerarin are always used together for cardiovascular disease in China clinics"><entity charOffset="20-28" id="DDI-PubMed.29790819.s2.e0" text="puerarin" /></sentence><sentence text=" This study investigates the effects of astragaloside IV (AS-IV, the main components of radix astragali) on the pharmacokinetics of puerarin in rats"><entity charOffset="40-56" id="DDI-PubMed.29790819.s3.e0" text="astragaloside IV" /><entity charOffset="132-140" id="DDI-PubMed.29790819.s3.e1" text="puerarin" /><pair ddi="false" e1="DDI-PubMed.29790819.s3.e0" e2="DDI-PubMed.29790819.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29790819.s3.e0" e2="DDI-PubMed.29790819.s3.e1" /></sentence><sentence text=" The pharmacokinetics of orally administered puerarin (50 mg/kg) with or without AS-IV pretreatment (100 mg/kg/day for seven days) were investigated"><entity charOffset="45-53" id="DDI-PubMed.29790819.s4.e0" text="puerarin" /></sentence><sentence text=" The plasma concentration of puerarin was determined using LC-MS/MS method, and the pharmacokinetics profiles were calculated and compared"><entity charOffset="29-37" id="DDI-PubMed.29790819.s5.e0" text="puerarin" /></sentence><sentence text=" Caco-2 cell transwell model was also used to investigate the effects of AS-IV on the transport pf puerarin"><entity charOffset="99-107" id="DDI-PubMed.29790819.s6.e0" text="puerarin" /></sentence><sentence text=" The results showed that when the rats were pretreated with AS-IV, the maximum concentration (Cmax) of puerarin decreased from 760 to 467 ng/mL (p &lt; "><entity charOffset="103-111" id="DDI-PubMed.29790819.s7.e0" text="puerarin" /></sentence><sentence text="05, n = 6, 90% CI, 293 ± 61" /><sentence text="28), and the area under the concentration-time curve from zero to infinity (AUC0-inf) also decreased from 4097 to 2330 μg·h/L (p &lt; " /><sentence text="05, n = 6)" /><sentence text=" The oral clearance of puerarin increased significantly from 11"><entity charOffset="23-31" id="DDI-PubMed.29790819.s11.e0" text="puerarin" /></sentence><sentence text="9 to 22" /><sentence text="4 L/h/kg (p &lt; " /><sentence text="05, n = 6)" /><sentence text=" The Caco-2 cell transwell experiments indicated that AS-IV could increase the efflux ratio of puerarin from 1"><entity charOffset="95-103" id="DDI-PubMed.29790819.s15.e0" text="puerarin" /></sentence><sentence text="81 to 2" /><sentence text="79 through inducing the activity of P-gp" /><sentence text=" In conclusion, these results indicated that AS-IV could affect the pharmacokinetics of puerarin, possibly by decreasing the systemic exposure of puerarin by inducing the activity of P-gp"><entity charOffset="88-96" id="DDI-PubMed.29790819.s18.e0" text="puerarin" /><entity charOffset="146-154" id="DDI-PubMed.29790819.s18.e1" text="puerarin" /><pair ddi="false" e1="DDI-PubMed.29790819.s18.e0" e2="DDI-PubMed.29790819.s18.e0" /><pair ddi="false" e1="DDI-PubMed.29790819.s18.e0" e2="DDI-PubMed.29790819.s18.e1" /></sentence><sentence text="" /></document>